Calypte Biomed mit Kursturbo
Seite 1 von 2 Neuester Beitrag: 24.09.03 15:24 | ||||
| Eröffnet am: | 24.09.03 14:16 | von: grenke | Anzahl Beiträge: | 35 |
| Neuester Beitrag: | 24.09.03 15:24 | von: Goldmarie | Leser gesamt: | 2.362 |
| Forum: | Hot-Stocks | Leser heute: | 2 | |
| Bewertet mit: |  | |||
| Seite: < | 2 > | ||||
Neues HIV-Testverfahren als Kursturbo (23.09.2003)
Die Experten des „Global Biotech Daily“ bekräftigen ihre Kaufempfehlung für die Aktie von Calypte Biomedical (WKN 765254). Die starken Kursschwankungen der vergangenen Woche sollten jetzt ein Ende finden, hierdurch kehrt wieder etwas Ruhe in den Wert. Der nächste Kursschub sollte aber unmittelbar bevorstehen, denn es ist wohl beschlossene Sache, dass die Weltgesundheitsorganisation (WHO) den Aids-Test von Calypte demnächst empfehlen wird. Somit könnte es zu einem Boom bei den Verfahren von Calypte kommen. Auch die Organisation World Vision Africa zeigt sich von den HIV-Urintests überzeugt und erteilte jüngst Calypte einen Auftrag in Höhe von vier Millionen Dollar. Mit diesem Testverfahren wird verhindert, dass sich Patienten während einer Untersuchung anstecken. Kurs aktuell: 1,16 Euro.
gruß Grenke
hab mich schon gewundert, dass heute noch kein CALY-Posting da war!
So long (oder doch besser short?)
Kalli 
Optionen
| Boardmail an "Kalli2003" |
Wertpapier: Calypte Biomedical |
1) der Kurs ist aktuell bei 1,24 €
2) von World vision war es kein Auftrag sondern eine Absichtserklärung (die aber zum Auftrag wird, bin mir sicher)
Soll keine Kritik sein, nur eine kleine Korrektur
Gruß
Jovi
hat wer vorbörsliche kurse?=)
thx kram
Ridgeland, MS, SEP 24, 2003 (EventX/Knobias.com via COMTEX) -- Company representatives of Calypte Biomedical Corporation (OTCBB: CYPT) will be presenting at the Friedland Capital Biotech, Medical and Healthcare Conference today. The Company's presentation is scheduled to begin at 10:00 ET.
Expected Speaker(s):
Antony Cataldo, Chairman
Misc Releated Info:
** Original Confirmation
** Conference Information:
Friedland Capital Biotech, Medical and Healthcare Conference
The event will feature presentations by the senior management of leading companies within these industries.
Conference Dates: 09/24/2003-09/24/2003
The Harvard Club
New York, NY
Phone: 303-355-6566
www.friedlandcapitalevents.com/...al%20Events%20Main%20Page%20New.htm
GET KNOBIAS IN REAL-TIME: Delivery of this proprietary Knobias alert has been delayed by at least 10 minutes. To get all Knobias alerts in real-time daily, visit www.knobias.com/cmtx
ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information.
Gruß, sireuitz.
(Sehe gerade, dass mein Anliegen schon besprochen wurde, allerdings empfinde ich solche "Korrekturen" als absolute Frechheit, was natürlich nicht grenke gilt, sondern dem kranken Verfasser der Kaufempfehlung.)
hatte dich noch gefragt letzte Woche - hätten wir schon mal kleine Caly Feete feiern können !!
Das war keine Kaufempfehlung von mir sonder meine Meinung, falls du lesen kannst schau es dir nochmal an und eine Korrektur ist keine Frechheit sondern eine Klarstellung von Tatsachen!!!
Jovi
--------------------------------------------------
Calypte Biomedical to Test its Urine Based HIV-1 Test in Tanzania, Rwanda, Burundi and Botswana
ALAMEDA, Calif., Sep 24, 2003 /PRNewswire-FirstCall via COMTEX/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test announced today that the company conducted meetings at the 13th International Conference on AIDS and Sexually Transmitted Infections (ICASA) being held in Nairobi, Kenya. These meetings allowed Calypte to present the case for urine HIV-1 testing before the top officials in Africa. Calypte's Urine based HIV-1 testing is FDA approved and is in growing demand in Africa.
Based on these meetings and previous discussions with individual government officials, Calypte Biomedical will initiate testing in Tanzania, Rwanda, Burundi, and Botswana.
Many countries want to move forward as quickly as possible on testing of the urine based product. With October funding proposals due, many countries have expressed the desire to utilize these funds for Calypte's urine based HIV-1 antibody tests.
Tony Cataldo, Calypte's Executive Chairman commented, "The momentum for international acceptance of Calypte's products has grown dramatically over the past several months and we anticipate that trend to continue. We believe that along with our recent funding and Calypte's experienced management team we are in a position to meet the increasing demand for our urine based HIV antibody tests."
About Calypte Biomedical:
Calypte Biomedical Corporation headquartered in Alameda, California, is a public healthcare company dedicated to the development and commercialization of urine-based diagnostic products and services for Human Immunodeficiency Virus Type 1 (HIV-1), sexually transmitted diseases and other infectious diseases. Calypte's tests include the screening EIA and supplemental Western Blot tests, the only two FDA-approved HIV-1 antibody tests that can be used on urine samples. The company believes that accurate, non-invasive urine-based testing methods for HIV and other infectious diseases may make important contributions to public health by helping to foster an environment in which testing may be done safely, economically, and painlessly. Calypte markets its products in countries worldwide through international distributors and strategic partners. Current product labeling including specific product performance claims can be found at www.calypte.com.
Statements in this press release that are not historical facts are forward-looking statements, including statements regarding announcements of financial results and presentations by the Company. Such statements reflect management's current views, are based on certain assumptions and involve risks and uncertainties. Actual results, events, or performance may differ materially from the above forward-looking statements due to a number of important factors, and will be dependent upon a variety of factors, including, but not limited to, our ability to obtain additional financing that will allow us to continue our current and future operations and whether demand for our product and testing service in domestic and international markets will continue to expand. The Company undertakes no obligation to publicly update these forward-looking statements to reflect events or circumstances that occur after the date hereof or to reflect any change in the Company's expectations with regard to these forward-looking statements or the occurrence of unanticipated events. Factors that may impact the Company's success are more fully disclosed in the Company's most recent public filings with the U.S. Securities and Exchange Commission ("SEC"), including its annual report on Form 10-K for the year ended December 31, 2002 and its subsequent filings with the SEC.
SOURCE Calypte Biomedical Corporation
Investor Relations - Tim Clemensen of Rubenstein Communications
for Calypte Biomedical Corporation, +1-212-843-9337,
tclemensen@rubensteinir.com
hätt mir ma nich grad 4mbo´s volx-pc holen sollen...
halbes jahr alt+mainboard pladd,gibt ersma n persönliches downgrade für 4mbo;(
daher hab ich das halbe we damit verbracht,meinen alten rechner wieder lauffähig zu machen
hab deshalb wohl auch deine einladung verpasst*sniff*
holen wa aber in kürze nach:D
kram
Sollte ich mich unklar ausgedrückt haben, so tut´s mir leid.
Gruß, sireuitz
hab euch doch alle lieb (wo sind meine Nussecken?)
Gruß
Jovi
Bin gespannt, wie weit diese ä#ußerst positiven Meldungen den Kurs treiben, ich denke, 2€ sind in kurzer Zeit möglich
Optionen
| Boardmail an "Realer" |
Wertpapier: Calypte Biomedical |
ALAMEDA, Calif., Sep 24, 2003 /PRNewswire-FirstCall via COMTEX/ -- Calypte Biomedical Corporation (OTC Bulletin Board: CYPT), the developer and marketer of the only two FDA approved HIV-1 antibody tests that can be used on urine samples, as well as an FDA approved serum HIV-1 antibody Western blot supplemental test announced today that the company conducted meetings at the 13th International Conference on AIDS and Sexually Transmitted Infections (ICASA) being held in Nairobi, Kenya. These meetings allowed Calypte to present the case for urine HIV-1 testing before the top officials in Africa. Calypte's Urine based HIV-1 testing is FDA approved and is in growing demand in Africa.
Based on these meetings and previous discussions with individual government officials, Calypte Biomedical will initiate testing in Tanzania, Rwanda, Burundi, and Botswana.
Many countries want to move forward as quickly as possible on testing of the urine based product. With October funding proposals due, many countries have expressed the desire to utilize these funds for Calypte's urine based HIV-1 antibody tests.
Tony Cataldo, Calypte's Executive Chairman commented, "The momentum for international acceptance of Calypte's products has grown dramatically over the past several months and we anticipate that trend to continue. We believe that along with our recent funding and Calypte's experienced management team we are in a position to meet the increasing demand for our urine based HIV antibody tests."
Optionen
| Boardmail an "Realer" |
Wertpapier: Calypte Biomedical |
Gruß
Jovi
Optionen
| Boardmail an "Realer" |
Wertpapier: Calypte Biomedical |